Costs of managing severe immune thrombocytopenia in adults: A retrospective analysis

Annals of Hematology

Volumn 90, Issue 4, 2011, Pages 441-446

  Khellaf, Mehdi ^a   Le Moine, Jean Gabriel ^b   Poitrinal, Priscille ^c   Francesconi, Camille ^b   Haddad, Albert ^c   Bierling, Philippe ^a   Michel, Marc ^a   Eckert, Laurent ^b   Launois, Robert ^b   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Réseau d'Evaluation en Economie de la Santé ^*  (France)

^c AMGEN INC   (United States)

Author keywords

Cost of illness; Immune thrombocytopenia; Resource utilisation

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENECTOMY; AGED; ECONOMICS; FRANCE; HEALTH CARE PLANNING; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; THROMBOCYTOPENIA; UTILIZATION REVIEW;

ADULT; AGED; COHORT STUDIES; FEMALE; FRANCE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 79955936964     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1087-x     Document Type: Article

References (23)

1. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3-40 (Pubitemid 26230668)
2. Godeau B, Provan D, Bussel J (2007) Immune thrombocytopenic purpura in adults. Curr Opin Hematol 14:535-556 (Pubitemid 47457646)
3. British Committee for Standards in Haematology General Haematology Task Force (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120:574-596
4. Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623-2634 (Pubitemid 39434940)
5. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT et al (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672-1681 (Pubitemid 44583957)
6. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, George JN et al (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371:395-403 (Pubitemid 351181334)
7. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161-2171, Erratum in: Blood. 2009;113: 4822
8. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641-648
9. McMillan R, Durette C (2004) Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104:956-960 (Pubitemid 39038013)
10. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C et al (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25-33 (Pubitemid 351650318)
11. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S et al (2008) Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura - results of a prospective multicenter phase 2 study. Blood 112:999-1004
12. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386-2393
13. Lauritsen JM (Ed.) (2000-2008) EpiData data entry, data management and basic statistical analysis system. Odense Denmark, EpiData Association. Available at http://www.epidata.dk. Accessed July 2010
14. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B (2005) Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 90:829-832 (Pubitemid 40897225)
15. Agence française de sécurité sanitaire des produits de santé. Tarification à l'activité (T2A) et médicaments hors du Groupe Homogène de Séjour (GHS). Available at http://www.afssaps.fr/Dossiers-thematiques/Tarification-a-l- activite-T2A-medicaments/Accueil-T2A/(offset)/0. Accessed 23 January 2009
16. Mauskopf J (1998) Prevalence-based economic evaluation. Value Health 1:251-259
17. Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197-1200
18. Danese MK, Lindquist K, Gleeson M, Deuson R, Mikhael J (2009) Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol 84:631-635
19. Gerdtham UG, Clarke P, Hayes A, Gudbjornsdottir S (2009) Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalisation data. Pharmacoeconomics 27:81-90
20. Agvall B, Borgquist L, Foldevi M, Dahlström U (2005) Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care 23:227-232 (Pubitemid 43378941)
21. Joyce AT, Smith P, Khandker R, Melin JM, Singh A (2009) Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 36:743-752
22. Ruggeri M, Fortuna SF, Rodeghiero FR (2009) The hospitalization need and cost of adult primary immune thrombocytopenia. Haematologica 94(Suppl 2), Abstract 0230
23. Tarantino M, Mathias SD, Snyder CF, Isitt JJ, Gernsheimer T, Young J (2010) Impact of immune thrombocytopenic purpura on physician visits and workplace productivity. Curr Med Res Opin 26:319-328